• SPX
  • 6086.49
  • 0.61 %
  • 36.6103
  • DJI
  • 45014.04
  • 0.69 %
  • 308.5078
  • N225
  • 39501.69
  • 0.57 %
  • 225.52
  • FTSE
  • 8335.81
  • -0.28 %
  • -23.6006
  • IXIC
  • 19735.115
  • 1.3 %
  • 254.2051
ImmunityBio, Inc. (IBRX) Stock Price, News & Analysis

ImmunityBio, Inc. (IBRX) Stock Price, News & Analysis

Currency in USD Disclaimer

$4.74

$0.18

(3.84%)

Day's range
$4.58
Day's range
$4.75
50-day range
$3.19
Day's range
$7.48
  • Country: US
  • ISIN: US45256X1037
52 wk range
$3.1
Day's range
$10.53
  • CEO: Mr. Richard Gerald Adcock
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -14.99
  • Piotroski Score 5.00
  • Grade Buy
  • Symbol (IBRX)
  • Company ImmunityBio, Inc.
  • Price $4.74
  • Changes Percentage (3.84%)
  • Change $0.18
  • Day Low $4.58
  • Day High $4.75
  • Year High $10.53

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 03/04/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $8.00
  • High Stock Price Target $8.00
  • Low Stock Price Target $8.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$1.08
  • Trailing P/E Ratio -5.65
  • Forward P/E Ratio -5.65
  • P/E Growth -5.65
  • Net Income $-583,196,000

Income Statement

Quarterly

Annual

Latest News of IBRX

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

ImmunityBio, Inc. Frequently Asked Questions

  • What is the ImmunityBio, Inc. stock price today?

    Today's price of ImmunityBio, Inc. is $4.74 — it has increased by +3.84% in the past 24 hours. Watch ImmunityBio, Inc. stock price performance more closely on the chart.

  • Does ImmunityBio, Inc. release reports?

    Yes, you can track ImmunityBio, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the ImmunityBio, Inc. stock forecast?

    Watch the ImmunityBio, Inc. chart and read a more detailed ImmunityBio, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is ImmunityBio, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by ImmunityBio, Inc. stock ticker.

  • How to buy ImmunityBio, Inc. stocks?

    Like other stocks, IBRX shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is ImmunityBio, Inc.'s EBITDA?

    ImmunityBio, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in ImmunityBio, Inc.’s financial statements.

  • What is the ImmunityBio, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -937.61414791, which equates to approximately -93,761.41%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in ImmunityBio, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including ImmunityBio, Inc.'s financials relevant news, and technical analysis. ImmunityBio, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for ImmunityBio, Inc. stock currently indicates a “sell” signal. For more insights, review ImmunityBio, Inc.’s technical analysis.

  • A revenue figure for ImmunityBio, Inc. for its last quarter?

    ImmunityBio, Inc. published it's last quarterly revenues at $6.11 M.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.